Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Finch Therapeutics Group (OTCPK:FNCHQ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Finch Therapeutics Group's Enterprise Value for the quarter that ended in Jun. 2024 was $15.15 Mil.
Finch Therapeutics Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group EV-to-EBIT Related Terms
Finch Therapeutics Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Finch Therapeutics Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's EV-to-EBIT falls into.
Finch Therapeutics Group's current Enterprise Value is $16.38 Mil.
Finch Therapeutics Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (FNCHQ) has a EV-to-EBIT of -0.83 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's EV-to-EBIT too high?
Finch Therapeutics Group's current EV-to-EBIT is -0.83. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's EV-to-EBIT compare to CRIS and LSB?
Finch Therapeutics Group's EV-to-EBIT of -0.83 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Finch Therapeutics Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Finch Therapeutics Group's current EV-to-EBIT is -0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current EV-to-EBIT of -0.83. The current EV-to-EBIT is -0.83. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current EV-to-EBIT is -0.83 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score
Get the complete analysis for FNCHQ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FNCHQ has been successfully added to your 
